DOJ’s Evolving Enforcement Approach to Off-Label Promotion

Published date29 April 2021
Subject MatterPharmaceutical Industry,Medical Devices,Off-Label Promotion,False Claims Act (FCA),Life Sciences,Prescription Drugs,DOJ,FD&C Act
AuthorJohn Bentivoglio,Jennifer Bragg,Maya Florence,William McConagha
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT